Aandelen in “Gezondheidstechnologie”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Gezondheidstechnologie”

8/12 · Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US · Persbericht

8/12 · Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US · Persbericht

8/12 · Jim Lang Elected to Halozyme's Board of Directors · Persbericht

8/12 · Shareholders who lost money in shares of Inspire Medical Systems, Inc. (NYSE: INSP) Should Contact Wolf Haldenstein Immediately · Persbericht

8/12 · Lilly declares first-quarter 2026 dividend · Persbericht

8/12 · Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India · Persbericht

8/12 · Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital · Persbericht

8/12 · Carolyn Bertozzi returns to Lilly board of directors · Persbericht

8/12 · CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT · Persbericht

8/12 · Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data · Persbericht

8/12 · Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting · Persbericht

8/12 · Nanalysis Announces $2.5 Million Private Placement · Persbericht

8/12 · UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder · Persbericht

8/12 · Karyopharm to Participate in Baird's Biotech Discovery Series · Persbericht

8/12 · Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand · Persbericht

8/12 · UCB toont veelbelovende fase 3-resultaten voor Fintepla · Bolero.be

8/12 · Virbac : Declaration of the number of shares and voting rights 11/2025 · Persbericht

8/12 · Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit · Persbericht

8/12 · Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 · Persbericht

8/12 · Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025 · Persbericht

8/12 · ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL · Persbericht

Mijn selecties